home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

70.50 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

Can AI Drive Peloton's Comeback? ↗

November 18, 2025

The market is hopping with interesting news.

Via The Motley Fool

Topics Artificial Intelligence

Down 55%, Should You Buy the Dip on Pfizer? ↗

November 17, 2025

Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.

Via The Motley Fool

Topics Intellectual Property

Is Pfizer Stock a Buy After This $10 Billion Acquisition? ↗

November 15, 2025

The company has been on an acquisition spree for years, and this one may be the most important yet.

Via The Motley Fool

Topics Intellectual Property Lawsuit

Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch ↗

November 10, 2025

Via Stocktwits

Topics Stocks

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗

November 14, 2025

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.

Via Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup ↗

November 14, 2025

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

November 14, 2025

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

November 14, 2025

There is hardly a dull moment for the drugmaker these days.

Via The Motley Fool

Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗

November 14, 2025

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Via Stocktwits

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗

November 13, 2025

CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.

Via Stocktwits

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? ↗

November 13, 2025

Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.

Via The Motley Fool

Topics Intellectual Property

Why Metsera's Share Price Is Plummeting This Week ↗

November 12, 2025

The biotech start-up's stock had been rising rapidly in 2025.

Via The Motley Fool

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India ↗

November 11, 2025

Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.

Via Benzinga

Where Will Pfizer Be in 3 Years? ↗

November 11, 2025

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Via The Motley Fool

Topics Intellectual Property

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗

November 11, 2025

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Via The Motley Fool

Shutdown Deal Breathes New Life Into Wall Street ↗

November 11, 2025

The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all...

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 10, 2025

Via Benzinga

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion ↗

November 10, 2025

The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.

Via Investor's Business Daily

Topics Initial Public Offering

Monday's pre-market session: top gainers and losers ↗

November 10, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗

November 08, 2025

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."

Via Benzinga

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy ↗

November 07, 2025

Via Benzinga

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com